MDGL - Madrigal Pharmaceuticals, Inc.
NEXT EARNINGS:
May 12, 2026
EPS Est: $-3.47
|
Rev Est: $303.1M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$705.67
DETAILS
HIGH:
$964.00
LOW:
$527.00
MEDIAN:
$640.00
CONSENSUS:
$705.67
UPSIDE:
60.38%
Market Cap:
9.99B
Volume:
266,626
Avg Volume:
325,291
52 Week Range:
265-615
Sector:
Healthcare
Industry:
Biotechnology
Beta:
-1.02
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
528
IPO Date:
2007-02-06
EPS (TTM):
-12.85
P/E Ratio:
-45.32
Revenue (TTM):
958.40M
Total Assets:
1.26B
Total Debt:
354.36M
Cash & Equiv:
198.69M
Rev Growth (5Y):
26.5%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-31.6%
Debt/Equity:
0.59
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-19 | $-2.57 | $0.04 | -6525.0% | $321.1M | $300.6M | +6.8% |
| 2025-11-04 | $-5.08 | $-2.04 | -149.4% | $287.3M | $245.0M | +17.3% |
| 2025-08-05 | $-1.90 | $-3.48 | +45.4% | $212.8M | $243.5M | -12.6% |
| 2025-05-01 | $-3.32 | $-3.62 | +8.3% | $137.2M | $158.9M | -13.6% |
| 2025-02-26 | $-2.71 | $-4.32 | +37.3% | $103.3M | $97.8M | +5.6% |
| 2024-10-31 | $-4.92 | $-6.94 | +29.1% | $62.2M | $92.5M | -32.8% |
| 2024-08-07 | $-7.10 | $-7.55 | +6.0% | $14.6M | $3.9M | +275.3% |
| 2024-05-07 | $-7.38 | $-6.06 | -21.8% | — | $3.9M | — |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 958.40M | 180.13M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (288.28M) | (465.89M) | (373.63M) | (295.35M) | (241.85M) | (202.24M) | (83.95M) | (32.81M) | (31.15M) | (26.39M) | (6.84M) | (86.16M) |
| EPS | -12.85 | -21.90 | -19.99 | -17.23 | -14.63 | -13.09 | -4.73 | -2.22 | -2.54 | -5.07 | -401.56 | -30.62 |
| Total Assets | 1.26B | 1.04B | 640.55M | 362.57M | 273.33M | 287.00M | 442.06M | 485.43M | 192.31M | 41.21M | 68.19M | 100.67M |
| Total Debt | 354.36M | 119.57M | 117.19M | 49.89M | 797,000 | 786,000 | 676,000 | 0 | 0 | 0 | 4.65M | 13.91M |
| Cash & Equivalents | 198.69M | 100.02M | 99.92M | 331.55M | 36.27M | 54.00M | 46.70M | 57.38M | 148.63M | 40.50M | 34.97M | 46.02M |
| Operating Cash Flow | (189.55M) | (455.57M) | (324.23M) | (224.86M) | (183.92M) | (157.56M) | (41.62M) | (25.51M) | (22.32M) | (17.61M) | (71.44M) | (78.92M) |
| Free Cash Flow | (190.02M) | (457.03M) | (325.71M) | (225.07M) | (184.13M) | (157.90M) | (41.80M) | (25.53M) | (22.44M) | (17.61M) | (71.50M) | (79.07M) |
| FCF per Share | -8.47 | -21.48 | -17.43 | -13.13 | -11.14 | -10.22 | -2.71 | -1.73 | -1.83 | -3.38 | -418.11 | -28.10 |
| Book Value | 602.69M | 754.38M | 405.33M | 197.39M | 196.11M | 239.97M | 416.56M | 476.98M | 182.26M | 36.41M | 50.41M | 65.14M |
| Cash & ST Investments | 983.56M | 926.25M | 634.13M | 358.77M | 270.35M | 284.15M | 439.05M | 483.72M | 191.53M | 40.50M | 66.57M | 97.69M |
| ROC Equity | -0.48 | -0.62 | -0.92 | -1.50 | -1.23 | -0.84 | -0.20 | -0.07 | -0.17 | -0.72 | -0.14 | -1.32 |